TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05816850

Intervention type: DIAGNOSTIC_TEST
Intervention: EZH2 mutations/CNAs by droplet digital PCR (ddPCR)
Description: Test of EZH2 mutations/CNAs by droplet digital PCR (ddPCR) in peripheral blood and in unsorted bone marrow aspirate samples at enrolment

Intervention type: DIAGNOSTIC_TEST
Intervention: EZH2-derived gene expression signature by RNA-Seq
Description: Test of EZH2-derived gene expression signature by RNA-Seq in a subset of diagnostic FFPE samples
Study: NCT06460883

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eccentric cable leg curls
Description: The players will undergo eccentric cable leg curls, completing 15 reps of 3 sets every other day with 30-45 seconds rest between sets, a total duration of 40 minutes conducted four days a week over a four-month training period.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: eccentric banded leg curls
Description: The players will undergo eccentric banded leg curls, completing 15 reps of 3 sets every other day with 30-45 seconds rest between sets, a total duration of 40 minutes conducted four days a week over a four-month training period.
Study: NCT05873868

Intervention type: OTHER
Intervention: Six minutes walk test
Description: Six minutes walk test just before first intake of treatment and after 1 and 2 years

Intervention type: OTHER
Intervention: Kansas City questionnaire
Description: Kansas City questionnaire just before first intake of treatment and after 1 and 2 years

Intervention type: OTHER
Intervention: COMPASS31 self questionnaire
Description: Compass31 self questionnaire assessing dysautonomia just before first intake of treatment and after 1 and 2 years
Study: NCT05884658

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vNOTES : natural vaginal orifice transluminal endoscopic system for hysterectomies
Description: hysterectomy via the vaginal approach by vNOTES (natural vaginal orifice transluminal endoscopic system for hysterectomies)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic hysterectomy
Description: laparoscopic hysterectomy uses a standardized procedure with or without surgical robot
Study: NCT06407817

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spencer technique
Description: No of repetitions; 3 sets for 10 repetitions with 1 minute rest between sets No Of Sessions Per Week: 3 Per Weeks for 6 weeks (40 Min per Session)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spencer technique
Description: No of repetitions; 3 sets for 10 repetitions with 1 minute rest between sets No Of Sessions Per Week: 3 Per Weeks for 6 weeks (40 Min per Session)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: reverse distraction technique
Description: No of repetitions; 10 ( Shoulder Abduction)10 ( Shoulder Flexion) 10 (Shoulder External Rotation) No Of Sessions Per Week: 3 Per Weeks for 6 weeks (40 Min Per Session)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: reverse distraction technique
Description: No of repetitions; 10 ( Shoulder Abduction)10 ( Shoulder Flexion) 10 (Shoulder External Rotation) No Of Sessions Per Week: 3 Per Weeks for 6 weeks (40 Min Per Session)
Study: NCT05728723

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Android Application
Description: Android Application for 3 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacy education
Description: Pharmacy education in hypertensive patients

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacy education
Description: Pharmacy education in hypertensive patients
Study: NCT06166927

Intervention type: DEVICE
Intervention: Cuffed endotracheal tube
Description: Patients will be intubated using a cuffed ETT with its OD determined by US measurement of the epiphyseal diameter of the distal radius.

Intervention type: DEVICE
Intervention: UnCuffed ETT
Description: Patients will be intubated using an uncuffed ETT (Flexicare-UK) with its OD determined by US measurement of the epiphyseal diameter of the distal radius.
Study: NCT05189977

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: Propranolol (tablet, oral ): 40 mg QD Day 3 and Day 21~Intervention 1 is a single dose of prazosin administered in the presence of sertraline alone at steady state or in the presence of sertraline + brexpiprazole at steady state.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: Propranolol (tablet, oral ): 40 mg QD Day 3 and Day 21~Intervention 1 is a single dose of prazosin administered in the presence of sertraline alone at steady state or in the presence of sertraline + brexpiprazole at steady state.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prazosin
Description: Prazosin (tablet, oral): 1 mg QD Day 2 and Day 20~Intervention 2 is a single dose of propranolol administered in the presence of sertraline alone at steady state or in the presence of sertraline + brexpiprazole at steady state.
Study: NCT05374837

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Infant and young child feeding voice messaging intervention
Description: A mobile voice and text messaging intervention aimed at improving IYCF practices will be delivered to mothers and fathers with young children (6-23 months). A total of 16 voice and text message, with the same content, will be sent over a 16-week period (1 voice + 1 text messages (with same content) per week x 16 weeks). Two types of messages will be included: 1) eight scripted and 2) eight unscripted messages from positive deviants. The content of the messages include: breastfeeding until two years of age, consuming a variety of foods within a given meal, the consistency of porridge (thick rather than thin), limiting sweets and fried foods, the importance of animal source foods, consuming vitamin A rich fruits and vegetables, consuming leafy greens, handwashing and feeding infants and young children fruits and vegetables produced by the household.
Study: NCT05311956

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: The study intervention will be participants self-applying 40 tDCS active stimulations with in-person supervision provided by trained study personnel. The self-applied intervention will continue 5 times per week over eight consecutive weeks. Treatment will occur in the home.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: In this arm of the study participants will self-apply 40 sham tDCS stimulations with in-person supervision provided by trained study personnel. The self-applied intervention will continue 5 times per week over eight consecutive weeks. Treatment will occur in the home.
Study: NCT05757063

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sedation with propofol
Description: After spinal anesthesia, patients will be sedated with propofol.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sedation with dexmedetomidine
Description: After spinal anesthesia, patients will be sedated with dexmedetomidine.
Study: NCT06310278

Intervention type: DIAGNOSTIC_TEST
Intervention: Ossicular mobility measurement
Description: Measurements of ossicular mobility i.e. the dynamic velocity of middle ear structures (umbo of malleus and incus at the incudostapedial joint) normalized to sound pressure incident on the tympanic membrane.
Study: NCT05254288

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Description: In-office and domiciliary use of chlorhexidine for 14 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Description: In-office and domiciliary use of chlorhexidine for 14 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ozoral gels
Description: In-office administration of Ozoral Pro and domiciliary use of Ozoral gel for 14 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ozoral gels
Description: In-office administration of Ozoral Pro and domiciliary use of Ozoral gel for 14 days.
Study: NCT06546280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab 200 mg will be administered by IV infusion on Day 1 of each 21-day cycle.
Study: NCT05981105

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ambIT pump with catheter
Description: 0.2% ropivacaine will be infused through a catheter pump at a rate of 10 ml/hr, 600 ml reservoir.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: ambIT pump with sham catheter
Description: sham catheter with no infusion
Study: NCT06361147

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychoeducational program for ASD
Description: 6 psychoeducation trainings for Autism Spectrum Disorder

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychoeducational program for ASD
Description: 6 psychoeducation trainings for Autism Spectrum Disorder

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychoeducational program for ASD
Description: 6 psychoeducation trainings for Autism Spectrum Disorder

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychoeducational program for ASD
Description: 6 psychoeducation trainings for Autism Spectrum Disorder
Study: NCT06509919

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood draw
Description: Before undergoing a prostate biopsy, participants will have about 10 mLs of venous blood drawn. Blood will be sent to Geneseeq Technology Inc. for whole genome high-throughput sequencing of plasma cfDNA.
Study: NCT06392776

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early diagnosis and treatment
Description: Early diagnosis of previously undiagnosed asthma or COPD and subsequent treatment by a primary care practitioner
Study: NCT04060355

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Savvy program
Description: Caregiver program (Savvy) is an evidence-based dementia family caregiver psychoeducation program. Provided to groups of 8-12 (typically) individuals caring for family members living with Alzheimer's disease or related dementias (PLWD), Savvy employs a mechanism of action based in Social Cognitive theory to promote caregivers' solution-focused coping behaviors through the acquisition of appropriate knowledge, skills, and outlook and the enhancement of caregiving mastery.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Semi-structured video interviews
Description: Semi-structured video interviews will assess the preliminary efficacy of programs led by system-trained interventionists in producing anticipated outcomes in caregiver participants - reduced depression and burden and enhanced caregiving mastery. It will also focus on sense of the completeness and adequacy of the training program, including the training methods, videos, and materials

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Semi-structured video interviews
Description: Semi-structured video interviews will assess the preliminary efficacy of programs led by system-trained interventionists in producing anticipated outcomes in caregiver participants - reduced depression and burden and enhanced caregiving mastery. It will also focus on sense of the completeness and adequacy of the training program, including the training methods, videos, and materials
Study: NCT06254495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGN-35C
Description: Given into the vein (IV; intravenously)
Study: NCT05189977

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prazosin
Description: Prazosin (tablet, oral): 1 mg QD Day 2 and Day 20~Intervention 2 is a single dose of propranolol administered in the presence of sertraline alone at steady state or in the presence of sertraline + brexpiprazole at steady state.
Study: NCT05369065

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Ablation Treatment
Description: Denervation of renal and common hepatic arteries by ethanol ablation with the Neurotronic Infusion Catheter

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Arterial Angiography Only
Description: Arterial Angiography Only without Intervention

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Single Arm non-Randomized Ablation Treatment
Description: Denervation of renal and common hepatic arteries by ethanol ablation with the Neurotronic Infusion Catheter
Study: NCT06546280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib 250 mg will be taken orally once daily.
Study: NCT06045481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: administration of single dose of doxycycline
Description: Postexposure prophylaxis with Single Dose doxycycline
Study: NCT05943925

Intervention type: OTHER
Intervention: No intervention
Description: no intervention

Intervention type: OTHER
Intervention: No intervention
Description: no intervention

Intervention type: OTHER
Intervention: No intervention
Description: no intervention

Intervention type: OTHER
Intervention: No intervention
Description: no intervention

Intervention type: OTHER
Intervention: No intervention
Description: no intervention

Intervention type: OTHER
Intervention: No intervention
Description: no intervention

Intervention type: DIETARY_SUPPLEMENT
Intervention: Probiotic supplement
Description: A total of 60 Alzheimer Disease (AD) patients will be recruited, 30 will ingest the probiotic mixture and 30 will ingest placebo (randomized assignment to the groups will be done). The experimental group will take the probiotic ingest daily: Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium bifidum, and Lactobacillus fermentum (2 × 109 colony forming units (CFU)/g of each). This mixture of bacteria has been showed to have positive results with 12 weeks treatment.

Intervention type: DIETARY_SUPPLEMENT
Intervention: Probiotic supplement
Description: A total of 60 Alzheimer Disease (AD) patients will be recruited, 30 will ingest the probiotic mixture and 30 will ingest placebo (randomized assignment to the groups will be done). The experimental group will take the probiotic ingest daily: Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium bifidum, and Lactobacillus fermentum (2 × 109 colony forming units (CFU)/g of each). This mixture of bacteria has been showed to have positive results with 12 weeks treatment.
Study: NCT03887741

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasmapheresis
Description: Patient will have monthly plasma exchange with young ApoE 33 plasma. Each exchange will be 1.5 volume of patient's plasma

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasma infusion
Description: Infuse every two weeks with ApoE33 young plasma (1unit) for 6 months
Study: NCT05468905

Intervention type: OTHER
Intervention: None of intervention
Description: None of intervention

Intervention type: OTHER
Intervention: None of intervention
Description: None of intervention
Study: NCT06132113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 764532
Description: BI 764532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 764532
Description: BI 764532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 764532
Description: BI 764532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 764532
Description: BI 764532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 764532
Description: BI 764532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Standard of care
Study: NCT06474442

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: BD111 Injection (investigational new drug)
Description: BD111: intrastromally injection, single-dosing RP2D (TU/eye), specified injection volume is 0.15mL.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Triple-drugs therapy of HSV-1 stromal keratitis
Description: Triple-drugs therapy: Ganciclovir Eye gel+Valacilovir Tablets+Prednisolone Acetate Eye Drops for 3 weeks.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Triple-drugs therapy of HSV-1 stromal keratitis
Description: Triple-drugs therapy: Ganciclovir Eye gel+Valacilovir Tablets+Prednisolone Acetate Eye Drops for 3 weeks.
Study: NCT04758312

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MY-Skills Mobile
Description: Yoga and Self-Management Education
Study: NCT06421012

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental : Patients without additional preoxygenation
Description: Throughout the entire period of their mechanical ventilation, patients will not receive additional preoxygenation before any endotracheal suctioning; their FiO2 value will be maintained constant

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator : Patients with additional preoxygenation
Description: Throughout the entire period of their mechanical ventilation, patients will receive additional preoxygenation at 100% FiO2 for a systematic 2-minute duration prior to any endotracheal suction. Subsequently, the FiO2 will be reset to the previous default value.
Study: NCT05468905

Intervention type: OTHER
Intervention: None of intervention
Description: None of intervention

Intervention type: OTHER
Intervention: None of intervention
Description: None of intervention

Intervention type: OTHER
Intervention: None of intervention
Description: None of intervention
Study: NCT04640636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine hydrochloride injection
Description: single IM injection of ketamine hydrochloride 0.5 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam injection
Description: single IM injection of midazolam 0.06 mg/kg
Study: NCT06577701

Intervention type: DRUG
Intervention: traditional Chinese medicine (TCM)
Description: Regulated use of Chinese medicine treatment protocols is included as an exposure factor. Exposure was defined as taking the medication continuously for more than 3 months per year, or taking the medication intermittently for more than 6 months per year. According to the standardised use of TCM protocols, the group was divided into an exposed group (TCM protocols cohort) and a non-exposed group (non-TCM protocols cohort).

Intervention type: DRUG
Intervention: non traditional Chinese medicine (non-TCM)
Description: Regulated use of Chinese medicine treatment protocols is included as an exposure factor. Exposure was defined as taking the medication continuously for more than 3 months per year, or taking the medication intermittently for more than 6 months per year. According to the standardised use of TCM protocols, the group was divided into an exposed group (TCM protocols cohort) and a non-exposed group (non-TCM protocols cohort).
Study: NCT06171087

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Domperidon
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral tablet
Study: NCT05414656

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Saddle contoured metal matrix, Pre-contoured self-adhesive matrix
Description: Saddle contoured metal matrix placed with the small clipper. The -contoured self-adhesive matrix has self adhesive ability.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Saddle contoured metal matrix, Pre-contoured self-adhesive matrix
Description: Saddle contoured metal matrix placed with the small clipper. The -contoured self-adhesive matrix has self adhesive ability.
Study: NCT05938959

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sham block
Description: Bilateral ESPB under ultrasound guidance bi-level Th3-6 and Th9-L1(adjusted to the incision line): 0.3-0.5ml/kg 0,9% normal saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ESPB
Description: Bilateral ESPB under ultrasound guidance bi-level Th3-6 and Th9-L1(adjusted to the incision line): 0.3-0.5ml/kg 0.2% Ropivacaine (max 2.5mg/kg)
Study: NCT06141772

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Measure of the circulating tumor DNA
Description: Blood assessment to measure the kinetics au circulating tumor DNA
Study: NCT04910061

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide mononucleotide (NMN-C)
Description: Daily supplementation with NMN-C at 400 mg for 29 days in total
Study: NCT06296771

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary energy restriction group (D)
Description: The participants allocated to the dietary energy restriction group will receive instructions to change their usual dietary intake and maintain their regular physical activity routine for the duration of eight weeks.~The dietary energy restriction depends on a total calorie deficit of 5000 kcal per week, achieved by the consumption of reduced meal portions. This deficit is computed by subtracting the participants\&#39; energy expenditure, as measured by ActiheartTM, rather than relying on reported energy intake. This approach is employed to reduce potential difficulties arising from participants under-reporting their food consumption. The energy deficit is calculated by multiplying the weight of each food item recorded over a 5-day period by an individual factor obtained from energy expenditure data. This calculation enables the determination of the required energy intake for the intervention period.
Study: NCT06435624

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intelligent rehabilitation robot training system
Description: Using an intelligent rehabilitation robot training system to simulate a real work environment, providing functional oriented treatment for stroke patients and improving upper limb motor function.~The instrument used is the Burt upper limb robot training system produced by Estun Medical Co., Ltd.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: repetitive facilitative exercise
Description: Repetitive facilitative exercise (RFE) is a new technology that combines multiple sensory stimuli and achieves facilitation and reinforcement of the reconstruction of paralyzed neural pathways through repeated and extensive directional exercise.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: repetitive facilitative exercise
Description: Repetitive facilitative exercise (RFE) is a new technology that combines multiple sensory stimuli and achieves facilitation and reinforcement of the reconstruction of paralyzed neural pathways through repeated and extensive directional exercise.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional therapy
Description: Basic training, including passive joint movement and activities of daily living exercise.